2025 was anything but quiet for the aesthetics industry. Alongside a steady stream of regulatory changes, the year also saw notable product innovation and technology advances, as well as more discerning patient expectations that favoured long-term regeneration and holistic wellbeing over short-term fixes.
Taken together, these developments point to an industry under closer oversight, with increasing emphasis on evidence, accountability and longer-term treatment planning.
Regulation, complaints and accountability
Regulatory scrutiny remained a defining feature of aesthetic medicine in 2025, with changes from Australia’s health regulators reshaping expectations around cosmetic practice, advertising and prescribing.
In June, Ahpra announced updated cosmetic practice guidelines and advertising standards aimed at strengthening safeguards in a rapidly expanding sector. Effective on 2 September 2025, the guidelines sought to clarify expectations around practitioner training, patient assessment, informed consent and post-procedure care, as well as further guidance on how higher-risk non-surgical cosmetic procedures can – and can’t – be advertised. The changes sparked debate around patient safety, patient education empowerment, and the ‘power imbalance between practitioner and patient’.
Regulatory attention also extended to telehealth, with updated Ahpra guidance addressing prescribing models and ethical concerns linked to remote cosmetic consultations. The guidance underscored expectations around clinical assessment, continuity of care and appropriate prescribing, particularly in response to business models that decouple consultation from treatment delivery.
Beyond formal guidance, 2025 saw ongoing confusion around practical compliance issues, particularly regarding the buying, storage and handling of Schedule 4 cosmetic injectables. An enforcement crackdown on unlawful supply chains brought long-simmering concerns into sharp focus, exposing inconsistencies in how injectables are sourced and stored across the sector. The issue was especially destabilising for nurse-led clinics, many of which were forced to urgently reassess their supply arrangements, storage protocols and prescribing relationships amid uncertainty about responsibility and liability.
AMP also reported on rising notification volumes and persistent confusion arising from the TGA and Ahpra’s fragmented regulatory oversight of the Australian medical aesthetics industry. The heightened focus on advertising compliance, increased public scrutiny and rising Ahpra notifications left many practitioners feeling exposed and confused – and questioning whether Ahpra’s notifications system is fit for purpose.
Data, studies and clinical evidence
Several high-interest studies and datasets reported in 2025 shaped clinical discussion across surgical and non-surgical practice.
A large retrospective study analysing 42,720 outpatient plastic surgery cases provided one of the most detailed safety datasets to date. The findings reinforced that serious complications remain uncommon overall, while identifying higher-risk procedure categories and patient factors that warrant careful selection and peri-operative planning.
Breast implant safety data also drew attention, with European registry studies linking implant rupture to a significantly increased risk of capsular contracture. The findings reinforced the importance of long-term follow-up, patient counselling and clear discussion of lifetime implant management.
Metabolic medicine continued to intersect with aesthetic practice. Coverage of emerging research explored differences between muscle and fat loss, changes in tissue quality and facial volume, as well as early signals suggesting a potential association between GLP-1 use and reduced botulinum toxin longevity.
GLP-1 RAs have also introduced new complexities into aesthetic surgery. Beyond increased demand for post-weight-loss procedures, these medications are altering perioperative management and prompted reassessment of anesthetic risk and fasting protocols.
As GLP-1 therapies extend their reach across multiple medical disciplines, their downstream aesthetic implications are likely to remain an area of active clinical and research interest.
Evolving clinical trends and protocols
Menopause and perimenopause emerged as a recurring clinical focus, driven by growing recognition of how hormonal change influences skin structure, facial volume, hair density and inflammatory response.
This shift has practical implications for treatment planning. Injectables, energy-based devices and regenerative protocols may behave differently in perimenopausal and postmenopausal patients, with implications for outcome durability, downtime and patient expectations. The increased visibility of menopause-focused education also reflects wider patient demand for clinicians who can contextualise aesthetic change within broader health transitions.
Across multiple therapeutic areas, there was a clear move toward protocol-based care, with greater focus on combination treatments and maintenance strategies. Rather than short-term transformation, treatment strategies increasingly prioritised gradual improvement that focus on longer term skin health and tissue quality.
Patients also placed greater value on skin integrity and biological health over immediate correction, driven in part by widespread filler fatigue and rising awareness of regenerative medicine. Interest in biologic and regenerative therapies, including exosomes and polynucleotides, continued to grow, reinforcing the shift toward outcomes that support tissue function rather than simple volumisation.
